Patents by Inventor Pierre Signore

Pierre Signore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050175657
    Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
    Type: Application
    Filed: December 2, 2004
    Publication date: August 11, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050169959
    Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
    Type: Application
    Filed: December 1, 2004
    Publication date: August 4, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050169958
    Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
    Type: Application
    Filed: December 1, 2004
    Publication date: August 4, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050165467
    Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 28, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
  • Publication number: 20050165488
    Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 28, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050158274
    Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 21, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050154454
    Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 14, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
  • Publication number: 20050154445
    Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 14, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
  • Publication number: 20050154453
    Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
    Type: Application
    Filed: November 29, 2004
    Publication date: July 14, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
  • Publication number: 20050149080
    Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
    Type: Application
    Filed: November 30, 2004
    Publication date: July 7, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050147643
    Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 7, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050147562
    Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 7, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050147599
    Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 7, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050149158
    Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
    Type: Application
    Filed: November 29, 2004
    Publication date: July 7, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050149173
    Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
    Type: Application
    Filed: November 10, 2004
    Publication date: July 7, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
  • Publication number: 20050149175
    Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 7, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
  • Publication number: 20050148512
    Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
    Type: Application
    Filed: November 10, 2004
    Publication date: July 7, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050143817
    Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
    Type: Application
    Filed: December 7, 2004
    Publication date: June 30, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
  • Publication number: 20050142163
    Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
    Type: Application
    Filed: December 1, 2004
    Publication date: June 30, 2005
    Applicant: Angiotech International AG
    Inventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins